Collaboration Brings Success

Diabetes Australia has welcomed the announcement by Minister for Health and Aged Care, Hon Mark Butler MP, that Fiasp insulin will continue to be available on the Pharmaceutical Benefits Scheme (PBS), a government scheme that subsidises the cost of medicines.

Minister Butler has announced the new listing of Fiasp Penfill which contains the same insulin (fast acting insulin aspart) in the same volume as the previously PBS listed Fiasp FlexTouch, but is delivered through a different device.

Over the last 6 months the Government has negotiated with Novo Nordisk to list Fiasp Penfill as a new form of the fast-acting insulin aspart. During this period, Diabetes Australia, along with health partner organisations the Australian Diabetes Society, Australian Diabetes Educators Association and politicians alerted by PDGN, have been lobbying to both Government and the Fiasp manufacturer, Novo Nordisk.

This announcement will bring significant relief for the 15,000 Australians living with diabetes who use Fiasp.

Advocacy Action – Are you aware of any diabetes treatments that your government seeks to change? These could be insulins, medicines, medical technology etc. If you do, let PDGN know. We may be able to help your campaign to save them.